Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium

The current gold standard for prostate cancer treatment is androgen deprivation therapy and antiandrogenic agents. However, adverse cardiovascular events including heart failure can limit therapeutic use. Istaroxime, which combines Na(+)-K(+)-ATPase (NKA) inhibition with sarco/endoplasmic reticulum...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Wallner, Markus, Khafaga, Mounir, Kolesnik, Ewald, Vafiadis, Aris, Schwantzer, Gerold, Eaton, Deborah M., Curcic, Pero, Köstenberger, Martin, Knez, Igor, Rainer, Peter P., Pichler, Martin, Pieske, Burkert, Von Lewinski, Dirk
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564766/
https://ncbi.nlm.nih.gov/pubmed/28514771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17540
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak